Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

Kimball A JohnsonNancy MartinRossella E NappiGenevieve Neal-PerryMarla ShapiroPetra StuteRebecca C ThurstonWendy WolfmanMarci EnglishCatherine FranklinMisun LeeKatherine Kuhn

Published in: The Journal of clinical endocrinology and metabolism (2023)

Daily fezolinetant 30 mg and 45 mg were efficacious and well-tolerated for treating moderate-to-severe VMS associated with menopause.

Keyphrases

high intensity
postmenopausal women
early onset
drug induced
depressive symptoms